GM1 gangliosidosis is an inherited neurodegenerative disorder caused by lysosomal beta-galactosidase deficiency, resulting in the storage of GM1 and GA1, primarily in the central nervous system. This disease typically afflicts infants and young children and there is currently no effective therapy. Substrate reduction therapy (SRT) could be of potential benefit. The imino sugars N-butyldeoxynojirimycin (NB-DNJ, miglustat, Zavesca) and N-butyldeoxygalactonojirimycin (NB-DGJ) used for SRT inhibi...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
If you are the owner of this record, you can report an update to it here: Report update to this record